Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low-dose Cytotoxics as "Anti-angiogenesis Treatment" Following Adjuvant Induction Chemotherapy for Patients With ER-negative and PgR-negative Breast Cancer

NCT00022516 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.

NCT NCT00022516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00022516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low-dose Cytotoxics as "Anti-angiogenesis Treatment" Following Adjuvant Induction Chemotherapy for Patients With ER-negative and PgR-negative Breast Cancer
Lead sponsor
ETOP IBCSG Partners Foundation
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2000
Completion date
August 31, 2016
Enrollment
1,086 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer